SecBot SecBot

INM

InMed Pharmaceuticals Inc.
Nasdaq· Pharmaceutical Preparations· Inc. A1· CIK 0001728328 Biotech & Drug Discovery
Former ticker of InMed Pharmaceuticals Inc. · MTRI stock page →
$19.87 +1.27 (+6.83%)
Nov 16 4:00 PM ET · prev $18.60
Market cap
$7.1M
Nano cap
1 year
+20.4%
from $16.50 · Nov 17
30 days
+45.6%
from $13.65
52-week range
$6.15–19.87
at the high
Avg volume 20D
25.8K
Nov 12 spike 145.6K
Short interest
63.4K
≈11.5% of shares · +855.8%
Days to cover
1.0
at average volume
Insider net
+$1.4M
2 buyers · 0 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
22
analyzed by SecBot
SecBot read MIXED 10 reports · 90 days
Balance 2 bearish · 1 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 8/10

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $1.4M. No open-market sales.

  • InstitutionsMIXED

    Q3 2026: 1 added (0 new), 0 trimmed or exited.

  • Short sellersBUILDING

    Short interest +855.8% to 63.4K shares. 1.0 days to cover, ≈11.5% of shares.

  • TrendUPTREND

    39% above its 50-day average. New closing high $19.87 on Nov 16.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
CITADEL ADVISORS LLCTRIM26,084$40.4K
UBS Group AGDOUBLED8,068$5.2K
Federation des caisses Desjardins du QuebecDOUBLED2$4.00
UBS Group AGADD7,762$25.2K
UBS Group AGTRIM6,106$12.6K
CITADEL ADVISORS LLCDOUBLED56,666$13.3K
HRT FINANCIAL LPDOUBLED38,369$8.0K
🔒 Fresh data, subscribers onlyADD

Quarterly 13F filings are due 45 days after each quarter ends.

Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent

Insider ledger

Form 4
$1.4M
bought · 2 insiders
$0
sold · 0 insiders
DateInsiderTypeValue
Oct 23, 2026
ADAR1 Capital Management, LLC
10%+ Owner
Oct 23, 2026
BUY$5.28
Oct 19, 2026
ADAR1 Capital Management, LLC
10%+ Owner
Oct 19, 2026
BUY$1.4K
Oct 16, 2026
ADAR1 Capital Management, LLC
10%+ Owner
Oct 16, 2026
BUY$1.32
Oct 15, 2026
ADAR1 Capital Management, LLC
10%+ Owner
Oct 15, 2026
BUY$1.3K
Oct 14, 2026
ADAR1 Capital Management, LLC
10%+ Owner
Oct 14, 2026
BUY$10.7K
Oct 13, 2026
ADAR1 Capital Management, LLC
10%+ Owner
Oct 13, 2026
BUY$750.12
Oct 8, 2026
ADAR1 Capital Management, LLC
10%+ Owner
Oct 8, 2026
BUY$3.0K
Oct 7, 2026
ADAR1 Capital Management, LLC
10%+ Owner
Oct 7, 2026
BUY$4.1K

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current QNoneNoneNo data$0.00
Next QNoneNoneNo data$0.00
Current FYNoneNoneNo data$0.00
Next FYNoneNoneNo data$0.00

Short side

FINRA· Oct 30, 2026
63,409
shares short
+855.8%
vs prior settlement
1.0
days to cover
≈11.5%
of shares outstanding
Trading halts
Nov 5, 2026Volatility PauseResumed
Nov 4, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 9, 2026 SEC
Mentari Therapeutics (formerly InMed Pharmaceuticals) completed its merger with Mentari Therapeutics and closed $490M…
8-K · Impact 5/10
Nov 9, 2026 Listing status
Delisted: INM, removed from the Nasdaq symbol directory
InMed Pharmaceuticals Inc. - Common Shares
Nov 5, 2026 SEC
InMed Pharmaceuticals (INM) reported shareholder approval of all proposals at its annual meeting, including a 1-for-10…
8-K · Impact 4/10
Nov 5, 2026 SEC
InMed Pharmaceuticals Inc. held its annual general and special meeting on November 4, 2026, where shareholders…
8-K · Impact 5/10
Oct 23, 2026 Insider
ADAR1 Capital Management, LLC bought 4 shares
10%+ Owner @ $1.32 ($5.28)
Oct 19, 2026 Insider
ADAR1 Capital Management, LLC bought 1,086 shares
10%+ Owner @ $1.32 ($1.4K)
Oct 16, 2026 Insider
ADAR1 Capital Management, LLC bought 1 shares
10%+ Owner @ $1.32 ($1.32)
Oct 15, 2026 Event
HSR Early Termination: InMed Pharmaceuticals Inc; Mentari Therapeutics, Inc.
The FTC granted early termination of the HSR Act waiting period for a transaction involving InMed Ph

SecBot reports

22 filings · 3 bullish · 9 bearish · 1 mixed · 9 neutral
All INM filing & press-release reports (22)